National Accounts Manager (Northeast)
We are proud to share:
We are proud to share:
- The New Drug Application (NDA) accepted for priority review by FDA for treatment of ALS. PDUFA data is June 29, 2022.
- The New Drug Submission (NDS) accepted for review by Health Canada for treatment of ALS.
- The MAA was validated by EMA in February 2022. We are building out our European team to be prepared to launch AMX0035 should the review result in a positive opinion.
- We are newly public, trading on NASDAQ under AMLX.
- Our team is 200 FTEs and growing strong!